Senseonics Holdings Inc (NYSE-American:SENS) reported on Sunday the extension of its distribution agreement with Roche Diabetes Care through to 31 January 2021.

The extended agreement allows Roche to continue as Senseonics' exclusive distributor in Europe, the Middle East and Africa, excluding Scandinavia and Israel.

This agreement now provides Roche with exclusive distribution rights in 17 additional countries, including Brazil, Russia, India and China, as well as select markets in the Asia Pacific and Latin American regions.

Additionally, Senseonics disclosed its unaudited preliminary revenue of USD8.0m for the fourth quarter of 2018 and USD19.7m for the full year 2018, respectively, up over USD2.9m for the fourth quarter of 2017 and USD6.4m for the full year 2017, respectively.

For the full year 2019, Senseonics expects revenues in the range of USD28.0m to USD32.0m.

Senseonics Holdings Inc is a medical technology company focused on the design, development and commercialisation of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease.The Eversense CGM System received PMA approval from the US FDA for up to 90 days of continuous use and is available in the US. The Eversense XL CGM System received CE mark for up to 180 days of continuous use and is available in Europe.